Solid Biosciences (SLDB) Payables (2017 - 2026)

Solid Biosciences has reported Payables for 10 years, with the latest figure at $8.9 million in Q1 2026.

• Quarterly Payables fell 20.7% year-over-year to $8.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.9 million (down 20.7% YoY) and the FY2025 annual result came in at $12.4 million, up 68.19% from the prior year.
• Payables fell to $8.9 million in Q1 2026 per SLDB's latest filing, from $12.4 million in the prior quarter.
• Over five years, Payables peaked at $15.0 million in Q3 2025 and troughed at $1.7 million in Q1 2024.
• A 5-year average of $6.3 million and a median of $5.1 million in 2022 frame the typical range for Payables.
• The sharpest annual moves came in 2024 and 2025: Payables slumped 69.08% in 2024, then soared 549.65% in 2025.
• Over 5 years, Payables stood at $3.2 million in 2022, then plunged by 37.25% to $2.0 million in 2023, then jumped by 263.53% to $7.4 million in 2024, then jumped by 68.19% to $12.4 million in 2025, then dropped by 28.26% to $8.9 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $8.9 million, $12.4 million, and $15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.